Chemistry:Ro48-6791
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C21H25FN6O2 |
| Molar mass | 412.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Ro48-6791 is a drug, an imidazobenzodiazepine derivative developed by Hoffman-LaRoche in the 1990s.[1]
Ro48-6791 was developed as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in induction of anaesthesia and conscious sedation for minor invasive procedures. Ro48-6791 has properties similar to those of midazolam, being water-soluble, with a fast onset and short duration of action. It is 4-6x more potent than midazolam,[2] and slightly shorter acting,[3] and produces similar side effects such as sedation and amnesia.
It was tested up to Phase II human trials, but while it produced less respiratory depression than propofol, it had a longer recovery time and was deemed not to have any significant advantages over the older drug.[4] Similarly when Ro48-6791 was compared to midazolam, it had similar efficacy, higher potency and a shorter recovery time, but produced less of a synergistic effect on opioid-induced analgesia and produced more severe side effects such as dizziness after the procedure.[5] Consequently, it was dropped from clinical development,[6] although it is still used in scientific research.[7]
See also
References
- ↑ US patent 5665718
- ↑ "Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects". British Journal of Clinical Pharmacology 44 (5): 477–86. November 1997. doi:10.1046/j.1365-2125.1997.t01-1-00612.x. PMID 9384465.
- ↑ "[RO 48-6791--a short acting benzodiazepine. Pharmacokinetics and pharmacodynamics in young and old subjects in comparison to midazolam]" (in German). Der Anaesthesist 45 (12): 1211–4. December 1996. doi:10.1007/s001010050360. PMID 9065257.
- ↑ "A phase 2 clinical trial comparing Ro 48-6791, a new short-acting benzodiazepine, with propofol for induction of anaesthesia". Anaesthesia and Intensive Care 26 (5): 509–14. October 1998. doi:10.1177/0310057X9802600506. PMID 9807605.
- ↑ "Comparison of the sedation and recovery profiles of Ro 48-6791, a new benzodiazepine, and midazolam in combination with meperidine for outpatient endoscopic procedures". Anesthesia and Analgesia 89 (4): 893–8. October 1999. doi:10.1097/00000539-199910000-00014. PMID 10512261.
- ↑ "When the drug trial fails: an approach to clinical drug studies". AANA Journal 67 (6): 505–12. December 1999. PMID 10876442.
- ↑ "Modelling acute tolerance to the EEG effect of two benzodiazepines". British Journal of Clinical Pharmacology 57 (2): 153–61. February 2004. doi:10.1046/j.1365-2125.2003.01964.x. PMID 14748814.
 |  |
